SCHEMBL13665243

SCHEMBL13665243

CN(C)C(=O)c1ccc2c(N)c(C(=O)Nc3ccc(Cl)cn3)oc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ RAB9A P51151 8/20 0.46
▸ NFKB1 P19838 3/20 0.46
▸ NFKB2 Q00653 3/20 0.46
▸ RELA Q04206 3/20 0.46
▸ TP53 P04637 3/20 0.46
▸ TSHR P16473 3/20 0.46
▸ NPC1 O15118 6/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ F10 P00742 9/20 0.45
▸ KCNH2 Q12809 2/20 0.45
▸ CYP2C19 P33261 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942487 0.92 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13665241 0.88 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL2947441 0.87 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13291234 0.86 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13665212 0.84 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13515797 0.82 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13665211 0.82 SORT1 (0.57) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13665204 0.82 RAB9A (0.55) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13665215 0.81 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANFKB1NFKB2RELA
SCHEMBL13665244 0.81 SMN1; SMN2 (0.55) SMN1; SMN2RAB9ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885RAB9A 4600/4885NFKB1 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback